453 related articles for article (PubMed ID: 25248887)
1. [Suppression of tumor antigen-specific T cell immune responses by regulatory T cells].
Shimazu Y; Nishikawa H
Gan To Kagaku Ryoho; 2014 Sep; 41(9):1057-61. PubMed ID: 25248887
[TBL] [Abstract][Full Text] [Related]
2. Regulatory T cells in cancer immunotherapy.
Nishikawa H; Sakaguchi S
Curr Opin Immunol; 2014 Apr; 27():1-7. PubMed ID: 24413387
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes.
Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF
Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.
Weber J
Semin Oncol; 2010 Oct; 37(5):430-9. PubMed ID: 21074057
[TBL] [Abstract][Full Text] [Related]
5. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy.
Mangsbo SM; Sandin LC; Anger K; Korman AJ; Loskog A; Tötterman TH
J Immunother; 2010 Apr; 33(3):225-35. PubMed ID: 20445343
[TBL] [Abstract][Full Text] [Related]
6. Cellular immune responses towards regulatory cells.
Larsen SK
Dan Med J; 2016 Jan; 63(1):B5188. PubMed ID: 26726907
[TBL] [Abstract][Full Text] [Related]
7. Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model.
Sundstedt A; Celander M; Eriksson H; Törngren M; Hedlund G
J Immunother; 2012 May; 35(4):344-53. PubMed ID: 22495392
[TBL] [Abstract][Full Text] [Related]
8. [Anti-CCR4 mAb and regulatory T cells].
Kurose K; Ohue Y; Oka M
Gan To Kagaku Ryoho; 2013 Sep; 40(9):1150-5. PubMed ID: 24047773
[TBL] [Abstract][Full Text] [Related]
9. Regulatory T cells in tumor immunity.
Nishikawa H; Sakaguchi S
Int J Cancer; 2010 Aug; 127(4):759-67. PubMed ID: 20518016
[TBL] [Abstract][Full Text] [Related]
10. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation.
Wolchok JD; Saenger Y
Oncologist; 2008; 13 Suppl 4():2-9. PubMed ID: 19001145
[TBL] [Abstract][Full Text] [Related]
11. Roles of regulatory T cells in cancer immunity.
Takeuchi Y; Nishikawa H
Int Immunol; 2016 Aug; 28(8):401-9. PubMed ID: 27160722
[TBL] [Abstract][Full Text] [Related]
12. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.
Mitsui J; Nishikawa H; Muraoka D; Wang L; Noguchi T; Sato E; Kondo S; Allison JP; Sakaguchi S; Old LJ; Kato T; Shiku H
Clin Cancer Res; 2010 May; 16(10):2781-91. PubMed ID: 20460483
[TBL] [Abstract][Full Text] [Related]
13. T regulatory cells in cancer: recent advances and therapeutic potential.
Elkord E; Alcantar-Orozco EM; Dovedi SJ; Tran DQ; Hawkins RE; Gilham DE
Expert Opin Biol Ther; 2010 Nov; 10(11):1573-86. PubMed ID: 20955112
[TBL] [Abstract][Full Text] [Related]
14. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells.
Alissafi T; Hatzioannou A; Legaki AI; Varveri A; Verginis P
J Autoimmun; 2019 Nov; 104():102310. PubMed ID: 31421963
[TBL] [Abstract][Full Text] [Related]
15. Comparison of vaccine-induced effector CD8 T cell responses directed against self- and non-self-tumor antigens: implications for cancer immunotherapy.
Pedersen SR; Sørensen MR; Buus S; Christensen JP; Thomsen AR
J Immunol; 2013 Oct; 191(7):3955-67. PubMed ID: 24018273
[TBL] [Abstract][Full Text] [Related]
16. Regulatory T cells in chronic hepatitis B patients affect the immunopathogenesis of hepatocellular carcinoma by suppressing the anti-tumour immune responses.
Zhang HH; Mei MH; Fei R; Liu F; Wang JH; Liao WJ; Qin LL; Wei L; Chen HS
J Viral Hepat; 2010 Mar; 17 Suppl 1():34-43. PubMed ID: 20586932
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.
Sasidharan Nair V; Elkord E
Immunol Cell Biol; 2018 Jan; 96(1):21-33. PubMed ID: 29359507
[TBL] [Abstract][Full Text] [Related]
18. Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells.
Khan S; Burt DJ; Ralph C; Thistlethwaite FC; Hawkins RE; Elkord E
Clin Immunol; 2011 Jan; 138(1):85-96. PubMed ID: 21056008
[TBL] [Abstract][Full Text] [Related]
19. <Editors' Choice> Meddling with meddlers: curbing regulatory T cells and augmenting antitumor immunity.
Kochin V; Nishikawa H
Nagoya J Med Sci; 2019 Feb; 81(1):1-18. PubMed ID: 30962651
[TBL] [Abstract][Full Text] [Related]
20. Considerations on clinical use of T cell immunotherapy for cancer.
Plautz GE; Cohen PA; Shu S
Arch Immunol Ther Exp (Warsz); 2003; 51(4):245-57. PubMed ID: 12956434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]